Cavidi

About Cavidi

In the world of diagnostics, it often starts in a university lab. For Cavidi, that story begins in 1984 at Uppsala University in Sweden, where two virologists founded the company. The name itself, Cavidi, is a nod to its origins: CAncer and VIrus DIagnostics. Their initial focus was on a specific enzyme, reverse transcriptase, to detect biomarkers for oncology and infectious diseases. The company's journey has been one of steady focus on complex problems, particularly HIV viral load monitoring in developing countries where traditional lab infrastructure is scarce. This dedication led to the development of diagnostic tests that could provide results comparable to PCR testing without the need for specialized equipment. A significant moment in their financial story occurred in 2018 when Cavidi secured an $11.5 million Series B funding round. This investment, led by the Swedish private equity firm Impilo, was aimed at launching their new automated diagnostic platform, Ziva™. This followed an earlier funding round in 2017 and a loan from the European Investment Bank, which marked its first institutional capital. This influx of capital was pivotal, enabling the company to expand its reach and bring its cost-effective monitoring solutions to high-disease burden countries.